Presentations will be available on the Alterity Therapeutics website here.

In a bid to retaliate against Paris, Algiers is rolling out the red carpet for a fringe Breton far-right group. This absurd ...

This RMAT designation is based on data from 3 clinical studies demonstrating the potential benefit of AAV-GAD as a one-time treatment for Parkinson’s disease - RMAT designation includes the benefits ...

These images depict dopamine-rich neural grafts in the brain of a Parkinsonian rat housed under Standard conditions (upper ...

Parkinson's disease (PD) is a disabling neurodegenerative disease that affects approximately 10 million people worldwide, ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...

Fast Track Designation highlights potential of ATH434 to address high unmet need for individuals with MSA – MELBOURNE, Australia and SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- Alterity ...

As an iron chaperone, it has excellent potential to treat Parkinson's disease as well as various Parkinsonian disorders such as Multiple System Atrophy (MSA). Phase 1 studies have demonstrated the ...

STOCKHOLM - 30 April 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today publishes its Interim Report January-March 2025. The full report is available on the Company's website.

Alzheimer’s Association Quality Control (QC) Program brings together laboratories across the globe with the aim of standardizing the measurement of Alzheimer's biomarkers. The program aims to monitor ...

Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today ...